PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
J Neurosci. Author manuscript; available in PMC Oct 7, 2008.
Published in final edited form as:
PMCID: PMC2562767
NIHMSID: NIHMS51378
The endogenous cannabinoid anandamide and its synthetic analog R(+)-methanandamide are intravenously self-administered by squirrel monkeys
Zuzana Justinova,1 Marcello Solinas,1,3 Gianluigi Tanda,2 Godfrey H. Redhi,1 and Steven R. Goldberg1
1Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland, 21224
2Psychobiology Section, Medications Discovery Research Branch, Intramural Research Program, National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services, Baltimore, Maryland, 21224
3Laboratoire de Biologie et Physiologie Cellulaire, Université de Poitiers, 86022, Poitiers, France
Correspondence should be addressed to Dr. Steven R. Goldberg, Preclinical Pharmacology Section, Behavioral Neuroscience Research Branch, NIDA, IRP, NIH, 5500 Nathan Shock Drive, Baltimore, MD 21224. E-mail: sgoldber/at/intra.nida.nih.gov
Anandamide, an endogenous ligand for brain cannabinoid CB1 receptors, produces many behavioral effects similar to those of Δ9-tetrahydrocannabinol (THC), the main psychoactive ingredient in marijuana. Reinforcing effects of THC have been demonstrated in experimental animals, but there is only indirect evidence that endogenous cannabinoids like anandamide participate in brain reward processes. We now show that anandamide serves as an effective reinforcer of drug-taking behavior when self-administered intravenously by squirrel monkeys. We also show that methanandamide, a synthetic long-lasting anandamide analog, similarly serves as a reinforcer of drug-taking behavior. Finally, we show that the reinforcing effects of both anandamide and methanandamide are blocked by pretreatment with the cannabinoid CB1 receptor antagonist rimonabant (SR141716). These findings strongly suggest that release of endogenous cannabinoids is involved in brain reward processes and that activation of cannabinoid CB1 receptors by anandamide could be part of the signaling of natural rewarding events.
Keywords: anandamide, cannabinoids, methanandamide, reinforcing effects, self-administration, squirrel monkey
Anandamide, the first identified endogenous ligand for brain cannabinoid receptors (Devane et al., 1992), activates cannabinoid CB1 receptors in the brain and produces many behavioral effects similar to, but less intense than, those of Δ9-tetrahydrocannabinol (THC) (Smith et al., 1994). Compared to THC, anandamide has a different chemical structure, a lower potency at cannabinoid CB1 receptors and a much shorter duration of action in vitro and in vivo due to rapid two-step inactivation by reuptake into neurons via presumed membrane transporters and subsequent intracellular degradation by fatty acid amide hydrolase (FAAH) (Piomelli, 2003; Freund et al., 2003). Most, but not all, pharmacological effects of THC are effectively inhibited by the CB1 receptor antagonist rimonabant (Rinaldi-Carmona et al., 1994) and rimonabant precipitates withdrawal signs in experimental animals chronically treated with THC (Ledent et al., 1999; Maldonado and Rodriguez de Fonseca, 2002; Tanda and Goldberg, 2003). In contrast, there are conflicting reports on the ability of rimonabant to inhibit behavioral actions of anandamide in rodents (Adams et al., 1998; Costa et al., 1999) and to precipitate withdrawal signs in rats chronically treated with anandamide (Aceto et al., 1998; Costa et al., 2000). Also, anandamide still produces cannabimimetic effects in cannabinoid CB1-receptor knockout mice (Di Marzo et al., 2000b). Finally, anandamide does not generally produce THC-like responding in monkeys and rats in drug-discrimination studies, although its longer lasting, metabolically stable, synthetic analogs, R(+)-methanandamide (methanandamide; Abadji et al., 1994) and O-1812 [(R)-(20-cyano-16,16-dimethyl docosa-cis-5,8,11,14-tetraenoyl)-1′-hydroxy-2′-propylamine], do show cross-discrimination with low doses of THC in rats (Jarbe et al., 2001; Maldonado and Rodriguez de Fonseca, 2002; Tanda and Goldberg, 2003; Wiley et al., 2004), suggesting that difficulties in demonstrating THC-like behavioral effects of anandamide may be due to its rapid inactivation and short duration of action rather than to qualitative differences between anandamide and THC. Most of these observations contribute to expectations that various means of facilitating the actions of endogenous anandamide for therapeutic purposes (Piomelli, 2003; Piomelli, 2004; Di Marzo et al., 2004) would have minimal abuse liability, although there have been no reported attempts to assess reinforcing effects of anandamide directly, with the exception of one negative finding with intraperitoneal anandamide using a conditioned place preference procedure in rats (Mallet and Beninger, 1998).
While reinforcing effects of THC have been clearly demonstrated in experimental animals (Tanda et al., 2000; Justinova et al., 2003), there is only indirect evidence that endogenous cannabinoids like anandamide participate in brain reward processes (van der Stelt and Di Marzo, 2003). For example, we have recently found that anandamide and its longer-lasting, metabolically-stable synthetic analog methanandamide increase extracellular dopamine levels in the shell of the nucleus accumbens, a marker of reinforcing effects for most drugs abused by humans (M. Solinas, Z. Justinova, S.R. Goldberg, and G. Tanda, unpublished observations). Here we directly investigated the reinforcing effects of anandamide and methanandamide using a primate model of human drug abuse previously employed successfully with THC (Tanda et al., 2000; Justinova et al., 2003) and other abused drugs (Goldberg, 1973).
Subjects
Nine adult male squirrel monkeys (Saimiri sciureus) weighing 0.9 to 1.1 kg were housed in individual cages in a temperature- and humidity-controlled room with unrestricted access to water. Monkeys were fed (approximately two hours after the session) a daily food ration consisting of five biscuits of high protein monkey diet (Lab Diet 5045, PMI Nutrition International, Richmond, Indiana) and two pieces of Banana Softies (Bio-Serv, Frenchtown, NJ) that maintained their body weights at a constant level throughout the study. Fresh fruits, vegetables and environmental enrichment were provided daily. Monkeys were maintained in facilities fully accredited by AAALAC and experiments were conducted in accordance with guidelines of the Institutional Care and Use Committee of the Intramural Research Program, NIDA, NIH, and Guidelines for the Care and Use of Mammals in Neuroscience and Behavioral Research (National Research Council 2003).
A group of six monkeys was used for experiments with anandamide self-administration: two monkeys were experimentally naïve, three had a history of THC self-administration and one had a history of methohexital self-administration (Table 1). With monkeys 1574, 1568, 6754 and 67F4 daily self-administration sessions at an anandamide dose of 40 μg/kg/injection were started after any prior drug-taking behavior was extinguished during 5 to 10 sessions of saline substitution under the 10-response, fixed-ratio (FR10) schedule of intravenous drug injection. One experimentally and drug naïve monkey (70F4) was first trained to press a lever for food pellets and 40 μg/kg intravenous injections of anandamide were then substituted for food, as described previously with THC (Justinova et al., 2003). In the other naïve monkey (66B2), 40 μg/kg injections of anandamide were initially made available under conditions where each press produced an injection (FR1) and the timeout value was 5 seconds; as the monkey learned to respond, the response requirement was gradually raised to ten (FR10) and the timeout value to one minute. For comparison with anandamide, three additional monkeys (01714B, 5045, 70F7) with stable cocaine self-administration behavior were studied at a cocaine dose of 30 μg/kg/injection that maintains maximal rates of responding under the present schedule conditions (Goldberg, 1973).
Table 1
Table 1
Reinforcing effects of anandamide in individual monkeys
Apparatus and self-administration procedure
Experimental chambers and other apparatus used in this study were the same as previously described in detail (Justinova et al., 2003). Monkeys were surgically prepared with chronic indwelling venous catheters (polyvinyl chloride), as described previously (Goldberg, 1973). The monkey’s catheter was connected to polyethylene tubing, which passed out of the isolation chamber where it was attached to a motor-driven syringe pump. Before the start of each session, monkeys were placed into the Plexiglas chairs and restrained in the seated position by waist locks. Before the start of each session, catheters were flushed with 1 ml of saline and one priming injection was delivered (calculated to fill the dead space of the IV catheter).
At the start of the session, the white house light was turned off and the green stimulus lights were turned on. In the presence of the green lights, monkeys were required to make 10 responses on the lever (10-response, fixed-ratio schedule of reinforcement; FR10) to produce an injection of anandamide or cocaine. The completion of 10 responses on the lever turned off the green lights and produced an IV injection of 40 μg/kg of anandamide or 30 μg/kg of cocaine paired with a 2-s illumination of the amber stimulus lights. Duration of each injection was 0.2 s and injection volume was 0.2 ml. Each injection was followed by a 60-s timeout period, during which the chamber was dark and lever presses had no programmed consequences. One-hour sessions were conducted five days per week (typically Monday to Friday).
When responding for 40 μg/kg injections of anandamide was stable for at least five consecutive sessions (less than 15% variability), self-administration behavior was extinguished by replacing anandamide with its vehicle for five consecutive sessions, followed by replacement of vehicle with 40 μg/kg injections of anandamide for additional 5 sessions. Next, an anandamide dose-effect curve was constructed by giving monkeys the opportunity to self-administer a range of anandamide doses (2.5, 10, 20, 40, 80 and 160 μg/kg/injection). Each anandamide dose was studied for five consecutive sessions and each dose-condition was separated by five consecutive sessions of vehicle extinction. This was followed by determination of a dose-effect curve for methanandamide (ranged from 2.5 – 80 μg/kg/injection) in four monkeys (66B2, 1568, 6754, 1574). Afterwards we studied the effects of 5-day pre-session treatment with 0.03 and 0.1 mg/kg rimonabant or its vehicle (given intramuscularly, i.m.; 60 minutes before session) on self-administration of the 40 μg/kg dose of anandamide and the effects of 0.1 mg/kg rimonabant on self-administration of the 40 μg/kg dose of methanandamide. Monkeys were injected with vehicle or rimonabant in the chair and were then returned to their home cage.
In the control group of monkeys responding for 30 μg/kg injections of cocaine, self-administration behavior was extinguished by replacing cocaine with its vehicle for five consecutive sessions, followed by replacement of vehicle with 30 μg/kg injections of cocaine. The dose 0.1 mg/kg of rimonabant was then tested for its effects on self-administration of the 30 μg/kg dose of cocaine.
Drugs
Anandamide (N-Arachidonylethanolamide) was purchased from Tocris Cookson, Inc. (Ellisville, MI) and was dissolved in a water-soluble emulsion (Tocrisolve; soya oil/water (1:4) emulsion) or in a vehicle containing 0.25% – 4% ethanol and 0.25% – 4% Tween 80 and saline. R(+)-Methanandamide (AM356; R(+)-Arachidonyl-1′-hydroxy-2′-propylamide) was purchased from Sigma Chemical Co. (St. Louis, MO) and was dissolved in a vehicle containing 0.125% – 4% ethanol and 0.125% – 4% Tween 80 and saline. (−)-Cocaine HCl was purchased from Sigma Chemical Co. (St. Louis, MO) and was dissolved in saline. Rimonabant (SR141716; N-piperidino-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxamide) was provided by the National Institute on Drug Abuse, NIH (Rockville, MD) and dissolved in a vehicle of 2% ethanol, 2% Tween 80 and saline.
Data analysis
Cumulative-response records were obtained during all sessions in order to assess within-session patterns of responding (Figure 3d, e, f). Abscissas represent time and ordinates represent cumulative lever-pressing responses. Short diagonal marks on the cumulative records indicate drug injections. After each injection, there was a time-out period during which the recorder did not operate. Pairs of diagonal hash marks represent deleted segments of the records, during which no responding occurred. Rates of responding during self-administration sessions are expressed as responses per second averaged over the one-hour session, with responding during time-outs not included in calculations. Injections per session represent total number of injections delivered per session. Data for dose-effect curves are expressed as mean response rates and numbers of injections per session ± SEM over the last three sessions. In addition, total intake of anandamide or methanandamide each session was calculated. Effects of pretreatment with rimonabant on drug self-administration are expressed as mean ± SEM of total numbers of injections per session as a function of consecutive daily self-administration sessions. For statistical evaluation of effects of rimonabant or vehicle extinction over consecutive sessions, the last session of vehicle pretreatment was always used as a control value to allow comparisons with subsequent sessions during pretreatment or extinction. Statistical analysis (SigmaStat program; Jandel Scientific, USA) was done using single-factor repeated measures ANOVA to assess differences between vehicle and test-drug pretreatment conditions or between different doses of anandamide or methanandamide and vehicle. Significant main effects were analyzed further by subsequent paired comparisons to control values using Dunnett’s test. Differences were considered statistically significant when p < 0.05.
Figure 3
Figure 3
Effects of rimonabant on responding maintained by anandamide (a), methanandamide (b) or cocaine (c) injections over consecutive sessions. Numbers of injections per session after i.m. pretreatment with vehicle (sessions 1–3) or 0.03 mg/kg or 0.1 (more ...)
Acquisition, extinction and reacquisition of anandamide self-administration
The monkeys learned to rapidly and repeatedly press a lever for intravenous injections of 40 μg/kg of anandamide (FR10 schedule) during one-hour daily sessions. By the end of the first week, all monkeys were consistently self-administering anandamide (16 – 53 injections per session depending on the individual monkey). However, another 2 to 9 weeks were required for acquisition of stable levels and characteristic “pause and run” patterns of FR lever-press responding under the final schedule conditions. In all of the monkeys, after acquisition, injections of 40 μg/kg anandamide maintained comparable high response rates (mean of 0.76 ± 0.12 response per second) and high numbers of self-administered injections each session (47.00 ± 1.33 injections per session) (Table 1). When vehicle injections were substituted for anandamide injections, rates of responding (F(5,20) = 7.69, p < 0.001), as well as number of injections self-administered per session (F(5,20) = 43.58, p < 0.001), decreased dramatically (Figure 1). When vehicle injections were replaced with 40 μg/kg injections of anandamide, self-administration behavior immediately recovered (F(5,20) = 94.45, p < 0.001) (Figure 1). The control group of monkeys responding for cocaine showed similar decreases in self-administration behavior when cocaine injections were replaced with vehicle injections (Figure 1).
Figure 1
Figure 1
Extinction and reacquisition of anandamide and cocaine self-administration behavior over consecutive sessions. Number of injections per session and overall rates of responding in the presence of a green light during 40 μg/kg/injection anandamide (more ...)
Self-administration of anandamide and methanandamide
Varying the injection dose of anandamide resulted in classic, inverted, U-shaped, dose-effect curves (Figure 2a, c, e). Anandamide maintained significantly higher rates of responding (F(6,24) = 11.93, p < 0.001) and higher numbers of injections per session (F(6,24) = 16.26, p < 0.001) than vehicle, with maximal responding (0.83 ± 0.09 response per second) and nearly the maximal possible number of injections per session (48.90 ± 0.96 injections per session) maintained by 40 μg/kg anandamide per injection.
Figure 2
Figure 2
Effects of varying injection dose on self-administration of anandamide and methanandamide. Number of injections of anandamide (a) and methanandamide (b) per session, overall rates of responding in the presence of the green light signaling anandamide ( (more ...)
Like anandamide, methanandamide maintained high rates and characteristic FR patterns of responding. When vehicle injections were substituted for methanandamide injections, rates of responding (F(5,10) = 13.94, p < 0.001), as well as number of injections self-administered per session (F(5,10) = 10.16, p < 0.001), decreased dramatically (data not shown). Again, after varying the injection dose of methanandamide, inverted U-shaped dose-effect curves were found (Fig. 2b, d, f). Methanandamide maintained significantly higher rates of responding (F(5,15) = 3.99, p = 0.017) and higher numbers of self-administered injections per session (F(5,15) = 13.94, p < 0.001) than vehicle at doses of 10, 20 and 40 μg/kg/injection, with maximal rates of responding averaging 0.71 ± 0.22 response per second and with a mean of 44.75 ± 3.21 injections per session at a dose of 40 μg/kg/injection.
Effects of cannabinoid CB1 receptor blockade on self-administration of anandamide, methanandamide and cocaine
A low dose 0.03 mg/kg of rimonabant did not produce significant changes in self-administration behavior for 40 μg/kg anandamide (injections: F(5,15) = 0.84, p = 0.545; rates of responding F(5,15) = 1.20, p = 0.357). A rimonabant dose of 0.1 mg/kg significantly decreased the number of self-administered injections of 40 μg/kg anandamide (F(5,15) = 11.51, p < 0.001; Figure 3a) or methanandamide (F(5,15) = 8.31, p < 0.001; Figure 3b) and rates of responding for anandamide (F(5,15) = 20.57, p < 0.001) and methanandamide (F(5,15) = 8.01, p < 0.001). Although, self-administration behavior was significantly reduced by pre-treatment with rimonabant, it remained slightly above vehicle substitution levels. In contrast, control monkeys responding for cocaine injections, showed no significant effect when treated with the 0.1 mg/kg dose of rimonabant (F(5,10) = 1.10, p = 0.420; Figure 3c), suggesting that rimonabant’s effects were not due to non-specific depressant effects on behavior.
The present experiments yielded three main findings. First, anandamide, like THC, cocaine and other abused drugs, serves as an effective reinforcer of drug-taking behavior when self-administered intravenously in squirrel monkeys. Rates of responding maintained by anandamide were comparable to those maintained under the same conditions for cocaine in a control group of monkeys in this study (1.23 ± 0.17 response per second and 51.78 ± 1.09 injections per session) and by cocaine and THC in our previous studies (Tanda et al., 2000; Justinova et al., 2003).
Second, methanandamide self-administration behavior was virtually identical to that maintained by anandamide, over the same range of injection doses, and intake of methanandamide and anandamide per session was similar despite their marked pharmacokinetic differences. Previous reported differences in behavioral effects of anandamide and methanandamide were found in tasks requiring relatively long-lasting effects over a session, such as discriminative-stimulus effects, disruption of learning, and inhibition of locomotion (Romero et al., 1996; Jarbe et al., 2001). Under those conditions, the brief half-life of anandamide could prevent measurement of significant effects. On the other hand, a short duration of effects favours demonstration of a high frequency of self-administered injections under FR10 self-administration procedures (Ko et al., 2002). In addition, previous marked differences between behavioral effects of anandamide and those of its synthetic analogs methanandamide and O-1812 were found using the intraperitoneal route of administration (Romero et al., 1996; Jarbe et al., 2001; Wiley et al., 2004), while in this study anandamide was delivered intravenously. It is possible that decreased hepatic first-passage metabolism with the intravenous route of administration greatly increased effects of anandamide, but not methanandamide which is resistant to metabolic inactivation by fatty acid amide hydrolase (FAAH). This is supported by our recent findings that intravenous injections of anandamide and methanandamide activate dopaminergic neurotransmission in the nucleus accumbens, as measured by extracellular dopamine levels, with similar peak intensity but with different durations of action (M. Solinas, Z. Justinova, S.R. Goldberg, and G. Tanda, unpublished observations).
Third, the reinforcing effects of both anandamide and methanandamide in squirrel monkeys appear to be mediated by cannabinoid CB1 receptors, since pre-session treatment with rimonabant dramatically decreased self-administration behavior of both cannabinoids. Rimonabant has been previously shown to block the reinforcing effects of THC (Tanda et al., 2000). It is unlikely that the effects of rimonabant were due to non-specific depressant effects on behavior since rimonabant did not affect responding for a highly reinforcing dose of cocaine in the control group of monkeys and does not depress responding for food under similar conditions (unpublished observations). These results highlight the fact that although some of anandamide’s effects have been attributed to other receptors, such as vanilloid VR1 receptors (Zygmunt et al., 1999) or uncharacterized new non-CB1, non-CB2, cannabinoid receptors (Breivogel et al., 2001; Hajos et al., 2001; Di Marzo et al., 2002; Pertwee, 2004), its reinforcing effects appear to be mediated mainly by cannabinoid CB1 receptors.
Of the many brain neurotransmitters, only a few have been clearly demonstrated to play direct roles in reward processes. Among the endogenous neurotransmitters, dopamine and endogenous opioids are the most clearly involved (Koob and Le Moal, 2001; Wise, 2004). The present findings provide compelling evidence for an important role of endogenous cannabinoids in brain reward processes. Previous studies have shown that cannabinoid CB1 receptor antagonists such as rimonabant can alter the reinforcing effects of abused drugs and food (Solinas et al., 2003; Solinas and Goldberg, 2005). Similar results have been found when cannabinoid CB1 receptors were genetically ablated (Ledent et al., 1999; Sanchis-Segura et al., 2004). Also, chronic treatment with abused drugs leads to changes in brain levels of endogenous cannabinoids in areas involved in motivational and reward processes (Di Marzo et al., 2000a; Gonzalez et al., 2002) and acute administration of a dopamine D2 receptor agonist increases extracellular levels of anandamide in the striatum (Giuffrida et al., 1999), suggesting that abused drugs do, indeed, release endocannabinoids, either directly, or indirectly through release of dopamine. Our finding that anandamide is actively self-administered by squirrel monkeys provides the first direct evidence for activation of brain reward processes by an exogenously administered endogenous cannabinoid and suggests that release of anandamide in the brain could be part of the signalling of natural rewarding events.
The present finding that anandamide is an effective reinforcer of intravenous self-administration behaviour in an animal model of human drug abuse suggests that medications that promote the actions of endogenously released cannabinoids could also activate brain reward processes and have the potential for abuse. This might be the case with medications which promote the actions of both anandamide and the more widely distributed endocannabinoid 2-arachidonylglycerol (2-AG) throughout the brain, e.g., by inhibiting their membrane transporter (Piomelli, 2003), resulting in widespread activation of cannabinoid CB1 receptors. However, it is believed that FAAH inhibitors promote the gradual accumulation of anandamide and augment CB1 signaling only in select brain areas where FAAH-positive cell bodies are juxtaposed to axon terminals that contain CB1 receptors (Piomelli, 2003; Di Marzo et al., 2004). Thus, FAAH inhibitors, which do not affect inactivation of 2-AG, would not necessarily be self-administered in a manner similar to our findings with rapid systemic injection of exogenous anandamide. As there are no published reports on reinforcing effects of inhibitors of endocannabinoid transport or FAAH inhibitors, their abuse potential remains to be resolved. Intravenous self-administration of anandamide by squirrel monkeys provides a novel procedure for studying the potential abuse liability of medications that activate endogenous cannabinoid systems and for investigating mechanisms involved in the reinforcing effects of endocannabinoids.
Acknowledgments
Work was supported by the Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health, Department of Health and Human Services. We thank Drs. Daniele Piomelli and Alexandros Makriyannis for helpful suggestions and comments during conduct of the research.
  • Abadji V, Lin S, Taha G, Griffin G, Stevenson LA, Pertwee RG, Makriyannis A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem. 1994;37:1889–1893. [PubMed]
  • Aceto MD, Scates SM, Razdan RK, Martin BR. Anandamide, an endogenous cannabinoid, has a very low physical dependence potential. J Pharmacol Exp Ther. 1998;287:598–605. [PubMed]
  • Adams IB, Compton DR, Martin BR. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J Pharmacol Exp Ther. 1998;284:1209–1217. [PubMed]
  • Breivogel CS, Griffin G, Di Marzo V, Martin BR. Evidence for a new G protein-coupled cannabinoid receptor in mouse brain. Mol Pharmacol. 2001;60:155–163. [PubMed]
  • Costa B, Vailati S, Colleoni M. SR 141716A, a cannabinoid receptor antagonist, reverses the behavioural effects of anandamide-treated rats. Behav Pharmacol. 1999;10:327–331. [PubMed]
  • Costa B, Giagnoni G, Colleoni M. Precipitated and spontaneous withdrawal in rats tolerant to anandamide. Psychopharmacology (Berl) 2000;149:121–128. [PubMed]
  • Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, Gibson D, Mandelbaum A, Etinger A, Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946–1949. [PubMed]
  • Di Marzo V, Berrendero F, Bisogno T, Gonzalez S, Cavaliere P, Romero J, Cebeira M, Ramos JA, Fernandez-Ruiz JJ. Enhancement of anandamide formation in the limbic forebrain and reduction of endocannabinoid contents in the striatum of delta9-tetrahydrocannabinol-tolerant rats. J Neurochem. 2000a;74:1627–1635. [PubMed]
  • Di Marzo V, Breivogel CS, Tao Q, Bridgen DT, Razdan RK, Zimmer AM, Zimmer A, Martin BR. Levels, metabolism, and pharmacological activity of anandamide in CB(1) cannabinoid receptor knockout mice: evidence for non-CB(1), non-CB(2) receptor-mediated actions of anandamide in mouse brain. J Neurochem. 2000b;75:2434–2444. [PubMed]
  • Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids. 2002;66:377–391. [PubMed]
  • Di Marzo V, Bifulco M, De Petrocellis L. The endocannabinoid system and its therapeutic exploitation. Nat Rev Drug Discov. 2004;3:771–784. [PubMed]
  • Freund TF, Katona I, Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol Rev. 2003;83:1017–1066. [PubMed]
  • Giuffrida A, Parsons LH, Kerr TM, Rodriguez de Fonseca F, Navarro M, Piomelli D. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999;2:358–363. [PubMed]
  • Goldberg SR. Comparable behavior maintained under fixed-ratio and second-order schedules of food presentation, cocaine injection or d-amphetamine injection in the squirrel monkey. J Pharmacol Exp Ther. 1973;186:18–30. [PubMed]
  • Gonzalez S, Cascio MG, Fernandez-Ruiz J, Fezza F, Di Marzo V, Ramos JA. Changes in endocannabinoid contents in the brain of rats chronically exposed to nicotine, ethanol or cocaine. Brain Res. 2002;954:73–81. [PubMed]
  • Hajos N, Ledent C, Freund TF. Novel cannabinoid-sensitive receptor mediates inhibition of glutamatergic synaptic transmission in the hippocampus. Neuroscience. 2001;106:1–4. [PubMed]
  • Jarbe TU, Lamb RJ, Lin S, Makriyannis A. (R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) 2001;156:369–380. [PubMed]
  • Justinova Z, Tanda G, Redhi GH, Goldberg SR. Self-administration of Delta(9)-tetrahydrocannabinol (THC) by drug naive squirrel monkeys. Psychopharmacology (Berl) 2003;169:135–140. [PubMed]
  • Ko MC, Terner J, Hursh S, Woods JH, Winger G. Relative reinforcing effects of three opioids with different durations of action. J Pharmacol Exp Ther. 2002;301:698–704. [PubMed]
  • Koob GF, Le Moal M. Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacology. 2001;24:97–129. [PubMed]
  • Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F, Bohme GA, Imperato A, Pedrazzini T, Roques BP, Vassart G, Fratta W, Parmentier M. Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1 receptor knockout mice. Science. 1999;283:401–404. [PubMed]
  • Maldonado R, Rodriguez de Fonseca F. Cannabinoid addiction: behavioral models and neural correlates. J Neurosci. 2002;22:3326–3331. [PubMed]
  • Mallet PE, Beninger RJ. Delta9-tetrahydrocannabinol, but not the endogenous cannabinoid receptor ligand anandamide, produces conditioned place avoidance. Life Sci. 1998;62:2431–2439. [PubMed]
  • Pertwee RG. Novel pharmacological targets for cannabinoids. Curr Neuropharmacol. 2004;2:9–29.
  • Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873–884. [PubMed]
  • Piomelli D. The endogenous cannabinoid system and the treatment of marijuana dependence. Neuropharmacology. 2004;47 Suppl 1:359–367. [PubMed]
  • Rinaldi-Carmona M, Barth F, Heaulme M, Shire D, Calandra B, Congy C, Martinez S, Maruani J, Neliat G, Caput D, Ferrara P, Soubrie P, Breliere JC, Le Fur G. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett. 1994;350:240–244. [PubMed]
  • Romero J, Garcia-Palomero E, Lin SY, Ramos JA, Makriyannis A, Fernandez-Ruiz JJ. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sci. 1996;58:1249–1257. [PubMed]
  • Sanchis-Segura C, Cline BH, Marsicano G, Lutz B, Spanagel R. Reduced sensitivity to reward in CB1 knockout mice. Psychopharmacology (Berl) 2004;176:223–232. [PubMed]
  • Smith PB, Compton DR, Welch SP, Razdan RK, Mechoulam R, Martin BR. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J Pharmacol Exp Ther. 1994;270:219–227. [PubMed]
  • Solinas M, Panlilio LV, Antoniou K, Pappas LA, Goldberg SR. The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl) -4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther. 2003;306:93–102. [PubMed]
  • Solinas M, Goldberg SR. Motivational effects of cannabinoids and opioids on food reinforcement depend on simultaneous activation of cannabinoid and opioid systems. Neuropsychopharmacology. 2005 doi: 10.1038/sj.npp.1300720. [PubMed] [Cross Ref]
  • Tanda G, Munzar P, Goldberg SR. Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci. 2000;3:1073–1074. [PubMed]
  • Tanda G, Goldberg SR. Cannabinoids: reward, dependence, and underlying neurochemical mechanisms-a review of recent preclinical data. Psychopharmacology (Berl) 2003;169:115–134. [PubMed]
  • van der Stelt M, Di Marzo V. The endocannabinoid system in the basal ganglia and in the mesolimbic reward system: implications for neurological and psychiatric disorders. Eur J Pharmacol. 2003;480:133–150. [PubMed]
  • Wiley JL, LaVecchia KL, Karp NE, Kulasegram S, Mahadevan A, Razdan RK, Martin BR. A comparison of the discriminative stimulus effects of Delta(9)-tetrahydrocannabinol and O-1812, a potent and metabolically stable anandamide analog, in rats. Exp Clin Psychopharmacol. 2004;12:173–179. [PubMed]
  • Wise RA. Dopamine, learning and motivation. Nat Rev Neurosci. 2004;5:483–494. [PubMed]
  • Zygmunt PM, Petersson J, Andersson DA, Chuang H, Sorgard M, Di Marzo V, Julius D, Hogestatt ED. Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature. 1999;400:452–457. [PubMed]